SCHEMBL1363095

SCHEMBL1363095

O=C(O)CCCC=Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.62
PAM P19021 2/20 0.60
TOP1 P11387 1/20 0.59
ALDH1A1 P00352 3/20 0.55
PPARA Q07869 3/20 0.54
GAA P10253 1/20 0.51
TBXA2R P21731 2/20 0.50
HDAC3 O15379 2/20 0.50
HDAC4 P56524 2/20 0.50
HDAC1 Q13547 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC2 Q92769 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
PPARG P37231 3/20 0.47
CYP19A1 P11511 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8798110 1.00 TBXAS1 (0.62) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL2379927 1.00 TBXAS1 (0.62) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL850919 0.94 TBXAS1 (0.69) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL850920 0.94 TBXAS1 (0.69) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL849353 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL8093646 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL5176079 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL849354 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL9303907 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA
SCHEMBL11606213 0.93 TBXAS1 (0.68) TBXAS1PAMTOP1ALDH1A1PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026280-B2 For therapy of cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. ERRANT GENE THERAPEUTICS, LLC (US) 2011-09-27 US claimed
EP-1566996-B1 METHOD OF PROTECTING SEEDS TREATED WITH A PHYTOTOXIC AGENT MONSANTO TECHNOLOGY LLC (US) 2009-11-11 EP claimed
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2024-11-14 US disclosed
US-20230080520-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2023-03-16 US disclosed
US-11604185-B2 Methods for detection of botulinum neurotoxin CITY OF HOPE (US) 2023-03-14 US disclosed
US-11278595-B2 Peptides comprising non-natural amino acids and methods of making and using the same LONGEVITY BIOTECH, INC. (US) 2022-03-22 US disclosed
US-20210255174-A1 METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN CITY OF HOPE (US) 2021-08-19 US disclosed
US-20210205415-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC 2021-07-08 US disclosed
US-20200384085-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME LONGEVITY BIOTECH, INC. 2020-12-10 US disclosed
US-10775366-B2 Substrates for detection of botulinum neurotoxin CITY OF HOPE (US) 2020-09-15 US disclosed
US-10772934-B2 Highly active polypeptides and methods of making and using the same LONGEVITY BIOTECH, INC. (US) 2020-09-15 US disclosed
EP-0807114-A1 BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-11-19 EP disclosed
EP-0509857-B1 Alpha-methylene 5-thiazolo acetic acid derivatives, intermediates and process of preparation, their use as fungicides and compositions containing them ROUSSEL UCLAF (FR) 1996-02-28 EP disclosed
EP-0509857-A1 Alpha-methylene 5-thiazolo acetic acid derivatives, intermediates and process of preparation, their use as fungicides and compositions containing them ROUSSEL UCLAF (FR) 1992-10-21 EP disclosed
EP-0123543-B1 LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION AND USE AND COMPOSITIONS CONTAINING THEM MERCK FROSST CANADA INC. (CA) 1988-02-03 EP disclosed
US-4609744-A 4-oxo-benzopyran carboxylic acids MERCK FROSST CANADA INC. (CA) 1986-09-02 US disclosed
US-4513005-A SULFIDE OR SULFONE HYDROXY ACIDS LILLY INDUSTRIES LIMITED (GB) 1985-04-23 US disclosed
EP-0068739-B1 SULPHUR-CONTAINING 5-HYDROXY-ALKANOIC ACID DERIVATIVES, THEIR USE AS PHARMACEUTICAL PREPARATIONS AND PROCESS FOR THEIR PRODUCTION Lilly Industries Limited (GB) 1984-11-14 EP disclosed
EP-0123543-A1 Leukotriene antagonists, their production and use and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-10-31 EP disclosed
EP-0068739-A1 Sulphur-containing 5-hydroxy-alkanoic acid derivatives, their use as pharmaceutical preparations and process for their production Lilly Industries Limited (GB) 1983-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11604185-B2 Methods for detection of botulinum neurotoxin ANTXR2, INHA, PRSS12 TBXAS1 479/4885PAM 1998/4885TOP1 2811/4885
US-20200384085-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME APLNR, SCTR, GIPR TBXAS1 1589/4885PAM 983/4885TOP1 4865/4885
US-20230080520-A1 PEPTIDES COMPRISING NON-NATURAL AMINO ACIDS AND METHODS OF MAKING AND USING THE SAME APLNR, SCTR, GIPR TBXAS1 1589/4885PAM 983/4885TOP1 4865/4885
US-20210255174-A1 METHODS FOR DETECTION OF BOTULINUM NEUROTOXIN ANTXR2, INHA, PRSS12 TBXAS1 479/4885PAM 1998/4885TOP1 2811/4885
US-10775366-B2 Substrates for detection of botulinum neurotoxin ANTXR2, INHA, PRSS12 TBXAS1 486/4885PAM 1977/4885TOP1 2934/4885
US-11278595-B2 Peptides comprising non-natural amino acids and methods of making and using the same APLNR, SCTR, GIPR TBXAS1 1589/4885PAM 983/4885TOP1 4865/4885
US-20210205415-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME SCTR, GIPR, APLNR TBXAS1 1665/4885PAM 1091/4885TOP1 4808/4885
US-10772934-B2 Highly active polypeptides and methods of making and using the same SCTR, GIPR, APLNR TBXAS1 1665/4885PAM 1091/4885TOP1 4808/4885
US-20240374689-A1 HIGHLY ACTIVE POLYPEPTIDES AND METHODS OF MAKING AND USING THE SAME SCTR, GIPR, APLNR TBXAS1 1665/4885PAM 1091/4885TOP1 4808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.